Skip to main content

Advertisement

Table 2 Incidence of clinical events in EINSTEIN DVT [25] and EINSTEIN PE [26]

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Probability, mean (SE) EINSTEIN DVT EINSTEIN PE
Recurrent VTE (LMWH/VKA)
3-month population
0–3 months 0.015 (0.008) 0.016 (0.011)
6-month population
0–3 months 0.024 (0.005) 0.016 (0.003)
3–6 months 0.003 (0.002) 0.002 (0.001)
12-month population
0–3 months 0.035 (0.009) 0.015 (0.004)
3–6 months 0.008 (0.004) 0.003 (0.002)
6–12 months 0.003 (0.003) 0.001 (0.001)
Lifelong population [61]
>12 months 0.700 (0.107) 0.700 (0.107)
Major bleeding (LMWH/VKA)
3-month population
0–3 months 0.020 (0.010) 0.041 (0.018)
6-month population
0–3 months 0.009 (0.003) 0.010 (0.003)
3–6 months 0.004 (0.002) 0.008 (0.003)
12-month population
0–3 months 0.002 (0.002) 0.013 (0.004)
3–6 months – (0.002) 0.004 (0.002)
6–12 months – (0.002) 0.006 (0.003)
Lifelong population [61]
>12 months 1.600 (0.245) 1.600 (0.245)
NMCR bleeding (LMWH/VKA)
3-month population
0–3 months 0.060 (0.017) 0.066 (0.022)
6-month population
0–3 months 0.047 (0.006) 0.067 (0.007)
3–6 months 0.013 (0.004) 0.022 (0.004)
12-month population
0–3 months 0.049 (0.01) 0.062 (0.008)
3–6 months 0.024 (0.008) 0.029 (0.006)
6–12 months 0.038 (0.01) 0.030 (0.006)
Lifelong population
>12 months 0.014 (0.002) 0.022 (0.002)
  1. LMWH, low molecular weight heparin; NMCR, non-major clinically relevant; SE standard error; VKA, vitamin K antagonist; VTE, venous thromboembolism.